Clinical updates, including trial initiations, enrollment status and data readouts and publications: Advaxis, Aeglea, Bio-Thera, Compugen, Galapagos, Incyte, Mirror, Synlogic, Transcenta, Vir.
LONDON – The message that COVID-19 is a disease of the elderly needs to change, according to U.K. researchers who have analyzed complications suffered by 73,197 patients admitted to 302 hospitals in the first wave of the pandemic last year.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alkeus, Antengene, Immunitybio, Kintor, Qualigen, Ryvu, Sesen.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Briacell, Cohbar, Cyxone, Escient, Kineta, Madrigal, Sirnaomics.
Nanodx Inc. entered into a license agreement with IBM Research to use IBM’s nanoscale sensor technology and develop diagnostic platforms for rapid and cost-effective detection of various diseases, including COVID-19 and traumatic brain injury, among others. This marks IBM’s first collaboration to allow a medical device company to use its nanoscale technology.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Atheart Medical, Curebase, Exagen, Inbios, Intuitap Medical, Medical Microinstruments, Pear Therapeutics, Spinex, Vessi Medical.
The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study showed that one of those vaccines, Sinovac Biotech Ltd.’s Coronavac, was less effective than Pfizer Inc. and Biontech SE’s Comirnaty in Chile.
RSS
